ICAD Icad Inc

iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that five clinical presentations and abstracts highlighting the Company’s advancements in breast cancer detection, risk evaluation, and breast arterial calcification (BAC) assessment have been accepted for presentation at the European Congress of Radiology (ECR) 2025, which will take place from February 26 to March 2, 2025, in Vienna, Austria.

Led by research collaborators, these studies underscore iCAD’s commitment to delivering artificial intelligence (AI) powered solutions to advance personalized risk assessment, enhance early detection, and optimize breast imaging workflows.

“At iCAD, we are committed to pushing the boundaries of AI innovation in breast health, and the research being presented at ECR 2025 underscores the real-world impact and potential of our solutions,” said Dana Brown, President and CEO of iCAD. “These studies highlight how our solutions are advancing personalized risk evaluation, improving early detection, optimizing breast imaging workflows, and expanding the application of AI insights from a mammograph beyond breast health, ultimately supporting better outcomes for patients and providers worldwide. In line with this commitment, iCAD will present the new ProFound Cloud, a secure, scalable SaaS platform designed to deliver the company’s advanced AI solutions to healthcare providers worldwide.”

Presentation Details:

Oral Presentations:

• RPS 1002 – Exploring the Role of AI in Breast ImagingFebruary 27, 14:00 – 15:30 CETTitle: A 10-year image-derived AI risk model for use in primary prevention of breast cancerPresenting Author: Mikael Eriksson, Stockholm, Sweden
• RPS 705 – Artificial Intelligence in Breast ImagingFebruary 27, 08:00 – 09:30 CETTitle: Optimal utilization of an AI diagnostic software in a mammography screening program in SwitzerlandPresenting Author: Marcel Blum, St. Gallen, Switzerland

• RPS 2202 – Personalized Risk Prediction of Breast CancerMarch 2, 08:00 – 09:00 CET
  • Title: Short-term risk prediction of breast cancer: Comparing risk tools for digital mammography and digital breast tomosynthesis in U.S. screening populationsPresenting Authors: Emily Conant, Chirag Parghi, Per Hall, and Mikael Eriksson
  • Title: Adding artificial intelligence (AI) case scoring in a breast screening program to optimize reading workflow and workload: A retrospective studyPresenting Author: Andrea Nitrosi, Reggio Emilia, Italy

EPOS Virtual Abstract Presentation:

• C-22811 (Virtual Poster) Title: Rapid Prototyping of a Breast Arterial Calcification Detection Algorithm with Human-in-the-Loop AnnotationAuthors: Yinhoa Ren, Jeff Hoffmeister, Jun Ge, Nikos Gkanatsios, Jonathan Go, Chirag Parghi, Emily Conant

iCAD will also showcase its latest AI-powered breast health innovations, including the ProFound Cloud which provides a fast, flexible and scalable access to iCAD’s ProFound full suite of solutions, including DBT Detection, 2D Detection, Density Assessment, and Risk. These presentations and live demonstrations at iCAD booth AI-27, Hall X-1 reinforce iCAD’s leadership in AI-driven breast health solutions, empowering radiologists with cutting-edge solutions to improve clinical outcomes, enhance workflow efficiency, and support personalized patient care. For more information about iCAD’s participation at ECR 2025 or to schedule a demonstration, visit: www.icadmed.com/about/news-events/upcoming-tradeshows-and-meetings/ecr-2025.

About iCAD, Inc.iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis.  For more information, including the latest in regulatory clearances, please visit www.icadmed.com.

Forward-Looking StatementsCertain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

CONTACTSMedia inquiries:pr@icadmed.com

Investor Inquiries:John Nesbett/Rosalyn ChristianIMS Investor Relations icad@imsinvestorrelations.com